



































A RANDOMIZED TRIAL OF THE DISCONTINUATION OF PRIMARY 



























































































































































 pneumonia is indicated in patients with human
immunodeficiency virus (HIV) infection who have less
than 200 CD4 cells per cubic millimeter and in those




 pneumonia. However, it is
not clear whether prophylaxis can be safely discon-
tinued after CD4 cell counts increase in response to




We conducted a randomized trial of the





 pneumonia in HIV-infected patients
with a sustained response to antiretroviral therapy,
defined by a CD4 cell count of 200 or more per cubic
millimeter and a plasma HIV type 1 (HIV-1) RNA level
of less than 5000 copies per milliliter for at least three
months. Prophylactic treatment was restarted if the





The 474 patients receiving primary pro-
phylaxis had a median CD4 cell count at entry of 342
per cubic millimeter, and 38 percent had detectable
HIV-1 RNA. After a median follow-up period of 20





 pneumonia in the 240 patients who
discontinued prophylaxis (95 percent confidence inter-
val, 0 to 0.85 episode per 100 person-years). For the 113
patients receiving secondary prophylaxis, the median
CD4 cell count at entry was 355 per cubic millimeter,
and 24 percent had detectable HIV-1 RNA. After a me-
dian follow-up period of 12 months (65 person-years),





the 60 patients who discontinued prophylaxis (95 per-





In HIV-infected patients receiving high-
ly active antiretroviral therapy, primary and second-




 pneumonia can be
safely discontinued after the CD4 cell count has in-
creased to 200 or more per cubic millimeter for more
than three months. (N Engl J Med 2001;344:159-67.)
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 pneumonia was a
common and often fatal infection in patients
infected with the human immunodeficien-





the use of primary prophylaxis became standard, the





the initial event defining the presence of the acquired
immunodeficiency syndrome (AIDS) was 62 percent,
and about 80 percent of patients with CD4 cell counts





 It was calculated that without secondary pro-
phylaxis, 50 percent of patients would relapse within








Chemoprophylaxis has been dramatically effective, and
it is currently recommended for all patients with less





oprim–sulfamethoxazole is the first choice for pro-
phylaxis, and it can be taken in double-strength form




 However, adverse effects of tri-
methoprim–sulfamethoxazole may occur in as many
as 50 percent of patients so treated, and 30 percent




The alternatives include aerosolized pentamidine, dap-





The use of highly active antiretroviral therapy has
changed the course of HIV infection, resulting in a
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persistent suppression of HIV replication leads to a
sustained increase in CD4 cells, even in patients with
severe immunosuppression. There have been several
reports of dramatic declines in the incidence of op-














 Recently, observational and ret-





phylaxis may be safely discontinued in patients re-





 A task force of
the U.S. Public Health Service and the Infectious Dis-
eases Society of America has recommended the dis-




pneumonia but recognizes that “the optimal criteria




In a randomized multicenter trial, we tested the





 pneumonia can be safely discontin-
ued in patients in whom highly active antiretroviral
treatment results in immune reconstitution, as long







Patients were eligible for the study if they had had previous CD4
cell counts of less than 200 per cubic millimeter or had had a pre-




 pneumonia; if they were receiving treat-




 pneumonia; if they had a sustained response to highly
active antiretroviral therapy, defined by a CD4 cell count of 200 or
more per cubic millimeter and a plasma HIV type 1 (HIV-1) RNA
level of less than 5000 copies per milliliter for more than three
months; and if they had a Karnofsky score higher than 80. Patients
were excluded if they were under 18 years of age, if they were preg-




The study was a randomized, nonblinded, multicenter trial that




 pneumonia can be safely discontinued in HIV-infected
patients. Patients were recruited from 19 Spanish public hospitals;
the staff at each had broad experience in the treatment and care
of HIV-infected patients. The randomization, based on permuted
blocks, was stratified according to center. The trial was approved
by the institutional review boards of the participating hospitals,
and all the patients gave written informed consent.





 pneumonia. Accepted regimens of
prophylaxis were those recommended in the 1997 guidelines of the





 Accepted highly active antiretroviral therapy involved at least
three antiretroviral drugs, one of which was a protease inhibitor





monia was diagnosed either after microbiologic confirmation in res-
piratory samples or when the clinical and radiographic presentation




 pneumonia and there was a




When the CD4 cell counts of patients assigned to discontinue pro-
phylaxis fell below 200 per cubic millimeter, prophylaxis was im-
mediately reinstituted, although the patients were kept in the study.
An increase in the HIV-1 RNA level was not a criterion for re-
starting prophylaxis.
Patients were evaluated at three-month intervals with a clinical
assessment and laboratory monitoring that included measurements
of CD4 cell counts and HIV-1 RNA levels, which were performed
at each site. Lymphocyte subpopulations were measured at all cen-
ters by three-color flow cytometry. HIV-1 RNA levels were de-
termined by either a polymerase-chain-reaction assay (Amplicor
HIV-1 Monitor Assay, Roche Molecular Systems, Somerville, N.J.)
or a branched-chain DNA assay (Chiron, Emeryville, Calif.). When
the study was designed, most of the hospitals used techniques with
a limit of detection of 400 copies per milliliter for the polymerase-
chain-reaction assay or 500 copies per milliliter for the branched-
chain DNA assay. Although by the end of the study all of the hos-
pitals were able to detect levels as low as 200 copies per milliliter
with the polymerase-chain-reaction assay or less than 50 copies per
milliliter with the branched-chain DNA assay, we kept 500 copies
per milliliter as the limit of detection for the HIV-1 RNA level
throughout the study.
 
End Points and Follow-up
 





 pneumonia. The secondary end points were




pneumonia (a “C” event as defined by the Centers for Disease Con-
trol and Prevention [CDC]), the occurrence of drug-related adverse
effects, the development of non–AIDS-defining bacterial infections,
changes in CD4 cell counts and HIV-1 RNA levels, and death. Pa-
tients were removed from the study during follow-up if one of the




pneumonia), hypersensitivity to the prophylactic agents, discontin-
uation of highly active antiretroviral therapy, or voluntary withdraw-
al from the study. A fall in CD4 cell counts to under 200 per cubic








 pneumonia would develop in 5 per-
cent of patients receiving primary prophylaxis during the 12 months





 We estimated that at least 200 patients at risk
would be needed in each group for the study to be able to detect
a 10 percent difference with 90 percent certainty and a 5 percent
significance level. Ten percent of patients were expected to be lost
to follow-up.




 pneumonia would develop in 15
percent of patients receiving secondary prophylaxis during the first





 We estimated that at least 30 pa-
tients at risk would be needed in each group to permit us to de-
tect a 45 percent difference with 90 percent certainty and a 5 per-
cent significance level. Ten percent of patients were expected to
be lost to follow-up.
An intention-to-treat analysis was performed. Medians and in-
terquartile ranges (25th to 75th percentile) were used as measures
of central tendency and dispersion. Confidence intervals for both
groups were calculated with the use of Poisson distribution tables.
For the base-line variables, comparisons between groups were made
with the chi-square test for categorical variables and the Mann–
Whitney nonparametric test for quantitative variables. Multivariate
analysis of variance with repeated measures was used to compare
CD4 cell counts at enrollment and at the first, second, third, and
fourth follow-up visits. A polynomial contrast was used to model the
within-group sum of squares, and a difference contrast was used to












 pneumonia were enrolled in the study between
January 1, 1998, and January 31, 1999. Of these,
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*CDC denotes Centers for Disease Control and Prevention, HAART highly active antiretroviral therapy, and CI confidence interval.
†Category A includes patients who have had no HIV-related diseases; category B includes patients who have had HIV-related diseases that are not in
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240 were randomly assigned to discontinue prophy-
laxis and 234 to continue it. The groups were well
balanced with regard to demographic characteristics
(Table 1). Most of the patients were men and had at
least a five-year history of HIV infection that includ-
ed a long period with a CD4 cell count of less than
200 per cubic millimeter. One hundred twenty-one
patients (54 in the group discontinuing prophylaxis
and 67 in the group continuing prophylaxis) had a
nadir CD4 cell count of no more than 50 per cubic
millimeter. Ninety-one percent were receiving pro-
phylaxis with trimethoprim–sulfamethoxazole. A to-
tal of 472 patients were receiving highly active anti-
retroviral therapy with a protease inhibitor and only
2 with a non-nucleoside reverse-transcriptase inhibi-
tor. At enrollment, patients had had more than 200
CD4 cells per cubic millimeter and less than 5000
copies of HIV-1 RNA per milliliter for a median of
8 months (range, 3 to 72). A total of 172 patients had
200 to 299 CD4 cells per cubic millimeter at enroll-
ment, and 169 were enrolled during the first 12
months of highly active antiretroviral therapy.
Of the 22 patients who dropped out of the study,
12 were lost to follow-up (7 assigned to discontinue
prophylaxis and 5 assigned to continue it), 3 discon-
tinued highly active antiretroviral therapy, 5 assigned
to continue prophylaxis discontinued it after enroll-
ment, and 2 in the group discontinuing prophylaxis
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decided to resume it because they were concerned
about the risk of P. carinii pneumonia. There were
no significant differences in base-line characteristics
between the patients who dropped out of the study
and those who remained in it. To our knowledge, only
a single patient (in the group continuing prophylaxis)
had P. carinii pneumonia after dropping out of the
study.
The median duration of follow-up was 20 months
(range, 16 to 24). The CD4 cell counts and the pro-
portion of patients with less than 500 copies of HIV-
1 RNA per milliliter during follow-up were similar in
the two groups (P=0.67 and P=0.41, respectively)
(Fig. 1). In 21 patients (9 in the group discontinuing
prophylaxis), CD4 cell counts fell below 200 per cubic
millimeter, and prophylaxis had to be reintroduced for
those in whom it had been discontinued. Ninety-two
patients in the group discontinuing prophylaxis and
89 in the group continuing prophylaxis had more than
500 copies of HIV-1 RNA per milliliter during 136
person-years of follow-up (group discontinuing pro-
phylaxis: median, 3250 copies per milliliter; range,
510 to 57,599; group continuing prophylaxis: medi-
an, 3458 copies per milliliter; range, 515 to 61,057).
During follow-up, the protease inhibitor was replaced
with a non-nucleoside reverse-transcriptase inhibitor
in 36 patients (17 in the group discontinuing prophy-
laxis and 19 in the group continuing prophylaxis).
There were no episodes of P. carinii pneumonia
in either group during follow-up — neither among
those with a nadir CD4 cell count of less than 50
per cubic millimeter before enrollment (95 percent
confidence interval, 0 to 4.6 episodes per 100 per-
son-years for the group discontinuing prophylaxis vs.
0 to 4.3 for the group continuing prophylaxis; P=
0.48) nor among those with more than 500 copies
of HIV-1 RNA per milliliter during follow-up (95
percent confidence interval, 0 to 4.0 episodes per 100
person-years for the group discontinuing prophylax-
is vs. 0 to 4.0 for the group continuing prophylaxis;
P=0.63). Two patients (one in each group) had a
“C” event, both with diagnoses of extrapulmonary
tuberculosis. Two patients (one in each group) died
of cancer (hepatic carcinoma and laryngeal carcinoma).
P. carinii pneumonia did not develop during follow-
up in any of the 21 patients whose CD4 cell counts
fell below 200 per cubic millimeter.
Fourteen patients (seven in each group) had an
infection during follow-up, including six with com-
munity-acquired pneumonia. In all of these patients,
P. carinii was ruled out as the cause of the infection
by microbiologic methods. No patient received em-
pirical anti–P. carinii treatment in therapeutic doses.
Drug-related adverse effects occurred in 49 patients
(23 in the group discontinuing prophylaxis and 26
in the group continuing prophylaxis); they were re-
lated in most patients to the use of protease inhibitors
and in 4 patients to the use of prophylactic agents
(3 of them discontinued prophylaxis). Finally, the
antiretroviral treatment had to be modified in 78 pa-
tients (41 in the group discontinuing prophylaxis and
37 in the group continuing prophylaxis), either be-
cause of adverse effects of the antiretroviral drugs or
because of virologic evidence of treatment failure.
Secondary Prophylaxis
Between January 1, 1998, and June 30, 1999, 113
patients who had had a previous episode of P. carinii
pneumonia were enrolled in the study. In 93 patients
(82 percent), the infection had been diagnosed by
microbiologic methods (48 in the group discontinu-
ing prophylaxis and 45 in the group continuing pro-
phylaxis). Sixty patients were randomly assigned to
discontinue prophylaxis. The characteristics of the pa-
tients who were receiving secondary prophylaxis at
study entry are shown in Table 2. Seventy-seven pa-
tients (68 percent) had a nadir CD4 cell count of less
than 50 per cubic millimeter, and 61 (54 percent)
were enrolled more than two years after the initial
episode of P. carinii pneumonia. Ninety-five patients
were receiving prophylaxis with trimethoprim–sul-
famethoxazole. In all patients, the initial highly ac-
tive antiretroviral therapy included a protease inhibitor,
which resulted in steady increases in the CD4 cell
counts. Twenty-seven patients (24 percent) had more
than 500 copies of HIV-1 RNA per milliliter during
follow-up (median, 1730; range, 506 to 26,494). The
changes in CD4 cell counts, the number of patients
with undetectable HIV-1 RNA levels, and the num-
ber of patients withdrawn from the study were sim-
ilar in the group assigned to discontinue secondary
prophylaxis and that assigned to continue prophy-
laxis (Table 2).
Two patients withdrew from the group discontinu-
ing prophylaxis (one stopped highly active antiretro-
viral therapy, and the other decided to resume pro-
phylaxis after Haemophilus influenzae pneumonia was
diagnosed). Neither has had P. carinii pneumonia
since they withdrew. After 65 person-years of follow-
up, there were no episodes of P. carinii pneumonia or
other “C” events in these patients (95 percent con-
fidence interval for the incidence of P. carinii pneu-
monia or other “C” events in the group discontinuing
prophylaxis, 0 to 4.57 episodes per 100 person-years
of follow-up; and in the group continuing prophylax-
is, 0 to 5.19 episodes per 100 person-years). The high-
ly active antiretroviral regimen was modified in five
patients in each group because of virologic evidence
of treatment failure or because of adverse effects. One
patient in each group had an episode of bacterial pneu-
monia.
DISCUSSION
This multicenter, randomized, nonblinded trial test-
ed the safety of discontinuing primary and secondary
prophylaxis against P. carinii pneumonia. We enrolled
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Figure 1. Mean CD4 Cell Counts and Proportions of Patients Who Had Undetectable HIV-1 RNA Levels
at Base Line (Month 0) and during Follow-up, According to Whether They Were Assigned to Discon-
tinue or Continue Primary Prophylaxis against P. carinii Pneumonia.
The bars represent 95 percent confidence intervals. Only data for the first 12 months of follow-up are
included because of the small number of patients followed for more than 1 year. The curves have been
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more than 500 patients at 19 Spanish hospitals. The
patients were representative of the HIV-infected pop-
ulation in our country; that is, most of them were
former intravenous drug users who had low CD4 cell
counts and had been infected with HIV for a long
period. Under these circumstances, P. carinii pneu-
monia can be expected to develop in a proportion
of patients not receiving prophylaxis. However, none
of them had an episode of P. carinii pneumonia after
the discontinuation of prophylaxis; this was the case
even among those receiving secondary prophylaxis,
those with low nadir CD4 cell counts, and those with
detectable HIV-1 RNA levels during follow-up. These
data suggest that both primary and secondary pro-
phylaxis against P. carinii pneumonia can be safely
discontinued in HIV-infected patients who have im-
proved immunologic function while receiving highly
active antiretroviral therapy, as long as the CD4 cell
count has remained at 200 or more per cubic milli-
meter for more than three months.
After the institution of highly active antiretroviral
therapy, there is improvement in various immunolog-
ic variables,27,28 and after several years immune recon-
stitution may be achieved.29,30 The effect of therapy
is reflected in a decrease in the incidence of opportun-
istic infections and death in HIV-infected patients.15-17
There are few studies of the discontinuation of primary
prophylaxis against P. carinii pneumonia in patients
with improved immunologic function during highly
active antiretroviral therapy. Most of the studies have
been observational, and P. carinii pneumonia devel-
oped in only one patient during follow-up.18-22 In a
recent randomized trial in Italy in which primary pro-
phylaxis against P. carinii was discontinued, no epi-
sodes of P. carinii pneumonia were reported after a
median follow-up of six months.31
All these data, as well as the results of our own
study, support the recommendation of the CDC that
primary prophylaxis be discontinued in patients who
have a sustained increase in the CD4 cell count to 200
or more per cubic millimeter for at least three to six
months. Although there are no guidelines for the re-
introduction of prophylaxis against P. carinii pneu-
monia, it is reasonable to resume it according to the
criteria used for primary prophylaxis — i.e., when the
CD4 cell count drops to less than 200 per cubic mil-
limeter.
Among the patients in our study, 113 had had a
previous episode of P. carinii pneumonia and were
receiving secondary prophylaxis. It is well known that
the risk of relapse after an initial episode is high with-
out secondary prophylaxis; in these cases, the inci-
dence of recurrent P. carinii pneumonia is 65 percent
in patients who survive for more than 18 months.4,32
Indeed, the 1999 CDC guidelines do not recom-
mend the discontinuation of secondary prophylaxis.
There are few data regarding the discontinuation of
prophylaxis in such patients, and most of the avail-
able data are from observational studies. An analysis
of several European observational studies identified
no cases of P. carinii pneumonia after 236 person-
years of follow-up in 246 patients who discontinued
prophylaxis.33 Taken together, these results and those
of our study — in which patients receiving second-
ary prophylaxis were randomly assigned to continue
or discontinue it — suggest that prophylaxis can be
discontinued even in patients who have had a previ-
ous episode of P. carinii pneumonia. However, this
group is at higher risk for P. carinii pneumonia than
those receiving primary prophylaxis, and patients who
discontinue secondary prophylaxis should remain un-
der close medical supervision.
Only two of our patients were receiving a non-
nucleoside reverse-transcriptase inhibitor at the time
of enrollment. Most previous studies of immune re-
constitution in HIV-infected patients have been per-
formed with the use of a protease inhibitor, and a
recent study suggests that these drugs may also have
activity against P. carinii.34 For all these reasons, dis-
continuation of prophylaxis should be undertaken
cautiously when patients are receiving protease-inhib-
itor–sparing regimens.
It is difficult to establish clear criteria for discon-
tinuing prophylaxis against P. carinii pneumonia af-
ter highly active antiretroviral treatment has begun.
We know the importance of the CD4 cell count and
the HIV-1 RNA level in the development of oppor-
tunistic infections.1,35-37 After the initiation of highly
active antiretroviral therapy, there have been reports
of opportunistic infections developing during the
first two or three months, especially in patients with
less than 50 CD4 cells per cubic millimeter.38,39 For
these reasons, our inclusion criteria for the discon-
tinuation of prophylaxis against P. carinii pneumonia
required that patients receive triple therapy resulting
in an increase in the CD4 cell count to 200 or more
per cubic millimeter and total or partial suppression of
viral replication for at least three months. New stud-
ies should be undertaken to determine whether it is
safe to discontinue prophylaxis when only one or two
of these criteria are met.
It has been suggested that patients receiving high-
ly active antiretroviral therapy that results in an in-
crease in CD4 cell counts to 200 or more per cubic
millimeter, but only partial suppression of viral repli-
cation, may not be as well protected as patients with
full viral suppression.40 Thirty-eight percent of our
patients who discontinued either primary or secondary
prophylaxis had more than 500 copies of HIV-1 RNA
per milliliter at some point during follow-up, and nei-
ther P. carinii pneumonia nor any other opportun-
istic infections developed in any of these patients. Our
data, as well as data from other studies,41,42 suggest
that the HIV-1 RNA level is less predictive of the
evolution of AIDS in patients receiving highly active
antiretroviral therapy who have CD4 cell counts of
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*HAART denotes highly active antiretroviral treatment, and CI confidence interval.
TABLE 2. MAIN CHARACTERISTICS OF PATIENTS DISCONTINUING SECONDARY PROPHYLAXIS 
















Male sex — no. (%) 45 (75) 41 (77)
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200 or more per cubic millimeter than in patients not
receiving highly active antiretroviral therapy.
In conclusion, the results of this randomized study
suggest that primary and secondary prophylaxis against
P. carinii pneumonia may be safely discontinued dur-
ing highly active antiretroviral therapy when the CD4
cell count has remained above 200 cells per cubic
millimeter for more than three months — even in pa-
tients with incomplete suppression of viral replication.
In the absence of further data, it seems prudent to re-
institute prophylaxis when the CD4 cell count drops
below 200 per cubic millimeter.
Supported by the Grupo de Estudio del SIDA de la Sociedad Española
de Enfermedades Infecciosas y Microbiología Clínica (GESIDA/SEIMC),
by the National AIDS Plan Secretariat of the Spanish Ministry of Health,
and by DuPont Pharma Laboratories.
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Infections, Chicago, January 31–February 4, 1999, and at the 39th Intersci-
ence Conference on Antimicrobial Agents and Chemotherapy, American So-
ciety for Microbiology, San Francisco, September 26–29, 1999.
We are indebted to Thomas O’Boyle for his assistance with the
English version of the manuscript.
APPENDIX
The members of the GESIDA 04/98 Study Group were as follows:
J. Berenguer, P. Miralles, and B. Padilla, Hospital Gregorio Marañón,
Madrid; B. Gómez and J.M. Gatell, Institut d’Investigacions Biomèdiques
August Pi I Sunyer and Hospital Clinic Universitari, Barcelona; J.R. Arribas
and J.J. Vazquez, Hospital La Paz, Madrid; M. Santín, E. Ferrer, and F. Gu-
diol, Ciutat Sanitaria de Bellvitge, L’Hospitalet; A. Pahissa, Hospital Gen-
eral Vall d’Hebron, Barcelona; J. Arrizabalaga, J.A. Iribarren, and M.A. von
Wichmann, Hospital Nuestra Señora de Aránzazu, Donostia; P. Viciana,
Hospital Virgen del Rocio, Seville; F. Laguna and E. Valencia, Hospital
Carlos III, Instituto de Salud Carlos III, Madrid; R. Rubio and F. Pulido,
Hospital 12 de Octubre, Madrid; F. Dronda, A. Antela, and S. Moreno,
Hospital Ramón y Cajal, Madrid; G. Sirera and B. Clotet, Hospital Ger-
mans Trias i Pujol, Badalona; C. Barros, Hospital General de Móstoles,
Madrid; D. Dalmau and X. Martinez-Lacasa, Mutua de Terrassa, Terrassa;
H. Knobel, Hospital de Nuestra Señora del Mar, Barcelona; K. Aguirre-
bengoa and M. Montejo, Hospital de Cruces, Vizcaya; J. Sola, Hospital de
Navarra, Pamplona; J. Gómez, Hospital Severo Ochoa, Madrid; J. Sanz,
Hospital Principe de Asturias, Madrid; and V. de Miguel, Agencia de En-
sayos Clínicos de GESIDA/SEIMC, Madrid — all in Spain. The members
of the GESIDA 04/98 steering committee were J.C. Lopez, J.M. Miro,
J.M. Peña, D. Podzamczer, X. Claramonte, J.C. Alberdi, and V. de Miguel.
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